WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

WashU Medicine and BJC Health System launch the Center for Health AI to enhance personalized, efficient care using AI, focusing on streamlining workflows, reducing clinician burnout, and improving patient outcomes.

An experimental vaccine shows promise against triple-negative breast cancer, with 16 of 18 patients remaining cancer-free 3 years post-vaccination, according to a study published in 'Genome Medicine'.

WashU Medicine and BJC Health System launch Center for Health AI to enhance personalized, effective, and efficient care through AI technologies.

Asha Therapeutics received a grant from the ALS Association for ASHA-624, a novel SARM1 inhibitor, to advance it to clinical trials for ALS. The company also appointed Disarm Therapeutics' founders to its Scientific Advisory Board.

Asha Therapeutics received an ALS Association grant to advance ASHA-624, a SARM1 inhibitor, for ALS treatment. Preclinical trials showed neuroprotection and motor function restoration. SARM1 experts Dr. Jeffrey Milbrandt, Dr. Aaron DiAntonio, and Dr. Jeffrey Rothstein joined Asha's Scientific Advisory Board.

Cofactor Genomics' OncoPrism-HNSCC, using RNA-sequencing and ML, improves prediction of head and neck cancer patient response to ICIs, outperforming PD-L1 CPS and TMB. The PREDAPT trial data showed 300% better specificity and 400% better sensitivity.

Matthew Powell discusses the expanded FDA approval of dostarlimab-gxly plus chemotherapy for advanced or recurrent endometrial cancer, supported by the RUBY trial, highlighting the significance of new treatment options for aggressive forms of the disease.

Cofactor Genomics published PREDAPT trial results in HNSCC, showing OncoPrism-HNSCC's 300% specificity and 400% sensitivity improvement over PD-L1 and TMB in predicting ICI benefit. OncoPrism-HNSCC aids clinicians in treatment decisions, published in the Journal for ImmunoTherapy of Cancer.